Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 1, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

January 31, 2026

Conditions
AmyloidosisLight Chain (AL) Amyloidosis
Interventions
DRUG

Bendamustine Hydrochloride

To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles

DRUG

Isatuximab

To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Tufts Medical Center

OTHER